EUCTR2012-005761-12-SK进行中（未招募）1 期
A Phase 4, Randomized, Double-blind, Placebo-controlled, Crossover Study to Investigate the Clinical Benefit of Midodrine Hydrochloride in Male and Female Subjects with Symptomatic Orthostatic Hypotension
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Male and female subjects must be 18 years of age or older and ambulatory (when receiving adequate therapy for their SOH).
- •2. Females of child-bearing potential (FOCP) must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test. These females should abstain from sexual activity that could result in a pregnancy, or agree to use acceptable contraceptives throughout the period of the entire study and for 30 days after the last dose of investigational product.
- •3. A documented history of severe SOH (eg, due to Parkinson’s disease, Shy-Drager syndrome, multiple system atrophy, pure autonomic failure, or autonomic neuropathies) that, in the judgment of the treating physician, has required treatment with midodrine HCl, and has been at a stable dose for at least 3 months.
- •4. The subject has manifested at least 1 of the following symptoms while standing or had a medical history of 1 of the following when not treated for orthostatic hypotension (OH): dizziness, lightheadedness, feeling faint, or feeling like they might black out.
- •5. The subject is willing and able to undergo the procedures required by the protocol, including inpatient stay as required, assessment completion, protocol compliance, and participation in the placebo dosing period(s).
- •6. The subject has adequate hydration status (as assessed by physical examination and clinical laboratory parameters, eg, urine specific gravity).
- •7. Ability to provide written, signed, and dated informed consent to participate in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 17
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1
排除标准
- •1. The subject is a pregnant or lactating female.
- •2. The subject has pre-existing sustained supine hypertension greater than 180mmHg systolic and 110mmHg diastolic BP or had these measurements at the Screening Visit. Sustained is defined as persistently greater at 2 separate measurements at least 5 minutes apart with the subject supine and at rest for the 5 minutes.
- •3. Subjects taking concomitant medications of interest are excluded unless those medications are reviewed and discussed with the Medical Monitor or Study Physician and documented prior to enrolling the subject. If agreement is reached between the Investigator and Sponsor for the subject to continue in the study, all allowed medications should be maintained at a constant dose throughout the study.
- •4. The Principal Investigator deems any clinical laboratory test (screening test) abnormality clinically significant.
- •5. The subject has participated in other studies of investigational drugs or devices within 30 days prior to enrollment in this study (other than Study SPD426-405).
- •6. Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational product or study procedures.
- •7. The subject has a concurrent chronic or acute illness, disability, or other condition (including significant unexpected laboratory or electrocardiogram [ECG] findings) that might confound the results of the tests and/or measurements administered in this study, or that might have increased the risk to the subject.
- •8. Known or suspected intolerance or hypersensitivity to the investigational product(s), closely-related compounds, or any of the stated ingredients.
- •9. Prior enrollment failure or randomization in this study.
- •10. History of alcohol abuse or other substance abuse within the last year.
研究者
相似试验
进行中（未招募）
1 期
A Phase 4 Randomized Controlled Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse HeadacheEUCTR2018-003342-16-ESAmgen Inc687
进行中（未招募）
1 期
A Phase 4 Randomized Controlled Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse HeadacheChronic migraineMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-003342-16-PTAmgen Inc620
进行中（未招募）
1 期
A Phase 4 Randomized Controlled Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse HeadacheChronic migraineMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-003342-16-ATAmgen Inc687
进行中（未招募）
1 期
A Phase 4 Randomized Controlled Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse HeadacheChronic migraineMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-003342-16-CZAmgen Inc687
进行中（未招募）
1 期
A Phase 4 Randomized Controlled Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse HeadacheEUCTR2018-003342-16-PLAmgen Inc620